Making life difficult for Clostridium difficile: Augmenting the pathogen's metabolic model with transcriptomic and codon usage data for better therapeutic target characterization

BMC Systems Biology

Volumn 11, Issue 1, 2017, Pages

  Kashaf, Sara Saheb ^a   Angione, Claudio ^b   Lió, Pietro ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b TEESSIDE UNIVERSITY   (United Kingdom)

Author keywords

Antibiotic resistance; Clostridium difficile; Flux balance analysis; Genome scale modeling; Metabolic modeling; Metabolic networks; Metabolic pathways; Sensitivity analysis

Indexed keywords

ANTIINFECTIVE AGENT; CODON;

BIOLOGICAL MODEL; CODON; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CODON; GENE EXPRESSION PROFILING; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 85013046059     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/s12918-017-0395-3     Document Type: Article

References (64)

1. Trudel JL. Clostridium difficile colitis. Clin Colon Rectal Surg. 2007; 20(1):13-7. doi: 10.1055/s-2007-970195.
2. Dubberke E. Clostridium difficile infection: the scope of the problem. J Hosp Med. 2012; 7 Suppl 3(March):1-4. doi: 10.1002/jhm.1916.
3. Janvilisri T, Scaria J, Thompson AD, Nicholson A, Limbago BM, Arroyo LG, Songer JG, Gröhn YT, Chang YF. Microarray identification of Clostridium difficile core components and divergent regions associated with host origin. J Bacteriol. 2009; 191(12):3881-91. doi: 10.1128/JB.00222-09.
4. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med. 2001; 161(4):525-33. doi: 10.1001/archinte.161.4.525.
5. Gerding DN, File TM, McDonald LC. Diagnosis and treatment of Clostridium difficile Infection. Infect Dis Clin Prac. 2016; 24(1):3-10. doi: 10.1097/IPC.0000000000000350.
6. Murima P, McKinney JD, Pethe K. Targeting bacterial central metabolism for drug development. Chem Biol. 2014; 21(11):1423-32. doi: 10.1016/j.chembiol.2014.08.020.
7. Wilkinson DJ. Stochastic modelling for quantitative description of heterogeneous biological systems. Nat Rev Genet. 2009; 10(2):122-33. doi: 10.1038/nrg2509.
8. Stephens M, Balding DJ. Bayesian statistical methods for genetic association studies. Nat Rev Genet. 2009; 10(10):681-90. doi: 10.1038/nrg2615.
9. Bordbar A, Monk JM, King ZA, Palsson BØ. Constraint-based models predict metabolic and associated cellular functions,. Nat Rev Genet. 2014; 15(2):107-20. doi: 10.1038/nrg3643.
10. O'Brien EJ, Monk JM, Palsson BØ. Using genome-scale models to predict biological capabilities. Cell. 2015; 161(5):971-87. doi: 10.1016/j.cell.2015.05.019.
11. Angione C, Lió P. Predictive analytics of environmental adaptability in multi-omic network models. Sci Rep. 2015; 5:15147. doi: 10.1038/srep15147.
12. Zelezniak A, Sheridan S, Patil KR. Contribution of network connectivity in determining the relationship between gene expression and metabolite concentration changes. PLoS Comput Biol. 2014;10(4). doi: 10.1371/journal.pcbi.1003572.
13. Larocque M, Chénard T, Najmanovich R. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors. BMC Syst Biol. 2014; 8(1):117. doi: 10.1186/s12918-014-0117-z.
14. Cheng J, Ma J, Lin J, Fan ZC, Cronan JE, Wang H. Only one of the five Ralstonia solanacearum long-chain 3-ketoacyl-acyl carrier protein synthase homologues functions in fatty acid synthesis. Appl Environ Microbiol. 2012; 78(5):1563-73. doi: 10.1128/AEM.07335-11.
15. Lobasso S, Palese LL, Angelini R, Corcelli A. Relationship between cardiolipin metabolism and oxygen availability in Bacillus subtilis. FEBS Open Bio. 2013; 3:151-5. doi: 10.1016/j.fob.2013.02.002.
16. Den Kamp JA, Redai I, van Deenen LL. Phospholipid composition of Bacillus subtilis. J Bacteriol. 1969; 99(1):298-303.
17. Ermolaeva MD. Synonymous codon usage in bacteria. Curr Issues Mol Biol. 2001; 3(4):91-7.
18. Futcher B, Latter GI, Monardo P, McLaughlin CS, Garrels JI. A sampling of the yeast proteome. Mol Cell Biol. 1999; 19(11):7357-368. doi: 10.1128/MCB.19.11.7357.
19. Klumpp S, Dong J, Hwa T. On ribosome load, codon bias and protein abundance. PLoS ONE. 2012;7(11). doi: 10.1371/journal.pone.0048542.
20. Orth JD, Thiele I, Palsson BØ. What is flux balance analysis?Nat Biotechnol. 2010; 28(3):245-8. doi: 10.1038/nbt.1614. http://arxiv.org/abs/NIHMS150003NIHMS150003.
21. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016; 44(D1):457-62. doi: 10.1093/nar/gkv1070.
22. Caspi R, Billington R, Ferrer L, Foerster H, Fulcher CA, Keseler IM, Kothari A, Krummenacker M, Latendresse M, Mueller LA, Ong Q, Paley S, Subhraveti P, Weaver DS, Karp PD. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 2016; 44(D1):471-80. doi: 10.1093/nar/gkv1164.
23. Thiele I, Palsson BØ. A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat Protoc. 2010; 5(1):93-121. doi: 10.1038/nprot.2009.203. http://arxiv.org/abs/NIHMS150003NIHMS150003.
24. Drucker DB, Wardle HM, Boote V. Phospholipid profiles of Clostridium difficile. J Bacteriol. 1996; 178(19):5844-6.
25. Parsons JB, Rock CO. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?Curr Opinion Microbiol. 2011; 14(5):544-9. doi: 10.1016/j.mib.2011.07.029.
26. Heinemann M, Kümmel A, Ruinatscha R, Panke S. In silico genome-scale reconstruction and validation of the Staphylococcus aureus metabolic network. Biotechnol Bioeng. 2005; 92(7):850-64. doi: 10.1002/bit.20663.
27. Ibarra RU, Edwards JS, Palsson BØ. Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth. Nature. 2002; 420(6912):186-9. doi: 10.1038/nature01149.
28. Schellenberger J, Que R, Fleming RM, Thiele I, Orth JD, Feist AM, Zielinski DC, Bordbar A, Lewis NE, Rahmanian S, et al. Quantitative prediction of cellular metabolism with constraint-based models: the cobra toolbox v2. 0. Nat Protoc. 2011; 6(9):1290-307. doi: 10.1038/nprot.2011.308.
29. Molenaar D, van Berlo R, de Ridder D, Teusink B. Shifts in growth strategies reflect tradeoffs in cellular economics. Mol Syst Biol. 2009; 5(323):323. doi: 10.1038/msb.2009.82.
30. Lee JS, Nishikawa T, Motter AE. Why optimal states recruit fewer reactions in metabolic networks. Discrete Continuous Dynamical Syst. 2012; 32(8):2937-50. doi: 10.3934/dcds.2012.32.2937. http://arxiv.org/abs/1206.07661206.0766.
31. Schuetz R, Kuepfer L, Sauer U. Systematic evaluation of objective functions for predicting intracellular fluxes in Escherichia coli. Mol Syst Biol. 2007; 3:119. doi: 10.1038/msb4100162.
32. García Sánchez CE, Torres Sáez RG. Comparison and analysis of objective functions in flux balance analysis. Biotechnol Prog. 2014; 30(5):985-91. doi: 10.1002/btpr.1949.
33. Sweetlove LJ, Ratcliffe RG. Flux-balance modeling of plant metabolism. Front Plant Sci. 2011; 2(August):1-10. doi: 10.3389/fpls.2011.00038.
34. Bui LT, Alam S. An introduction to multi-objective optimization. In: Multi-objective Optimization in Computational Intelligence: Theory and Practice: 2008. p. 1-19, doi: 10.4018/978-1-59904-498-9.
35. Sbalzarini IF, Muller S, Koumoutsakos P. Multiobjective optimization using evolutionary algorithms. In: Proceedings of the Summer Program.2000. p. 63-74.
36. Costanza J, Carapezza G, Angione C, Lió P, Nicosia G. Robust design of microbial strains. Bioinformatics. 2012; 28(23):3097-104. doi: 10.1093/bioinformatics/bts590.
37. Gurobi Optimization I. Gurobi Optimizer Reference Manual. 2016. http://www.gurobi.com. Accessed 20 Feb 2016.
38. Angione C, Costanza J, Carapezza G, Lió P, Nicosia G. Multi-target analysis and design of mitochondrial metabolism. PLoS ONE. 2015;10(9). doi: 10.1371/journal.pone.0133825.
39. Gorochowski TE, Ignatova Z, Bovenberg RAL, Roubos JA. Trade-offs between tRNA abundance and mRNA secondary structure support smoothing of translation elongation rate. Nucleic Acids Res. 2015:1-11. doi: 10.1093/nar/gkv199.
40. Nakamura Y, Gojobori T, Ikemura T. Codon usage tabulated from the international DNA sequence databases; its status 1999. Nucleic Acids Res. 1999; 27(1):292. doi: 10.1093/nar/27.1.292.
41. Bairoch A, Apweiler R, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh LSL. The universal protein resource (UniProt). Nucleic Acids Res. 2005;33. doi: 10.1093/nar/gki070.
42. Lee S, Weon S, Lee S, Kang C. Relative codon adaptation index, a sensitive measure of codon usage bias. Evol Bioinforma. 2010; 2010(6):47-55. doi: 10.4137/EBO.S4608.
43. Angione C, Conway M, Lió P. Multiplex methods provide effective integration of multi-omic data in genome-scale models. BMC Bioinforma. 2016; 17(S4):83. doi: 10.1186/s12859-016-0912-1.
44. Firczuk H, Kannambath S, Pahle J, Claydon A, Beynon R, Duncan J, Westerhoff H, Mendes P, McCarthy JE. An in vivo control map for the eukaryotic mRNA translation machinery. Mol Syst Biol. 2013; 9(635):635. doi: 10.1038/msb.2012.73.
45. Angione C, Pratanwanich N, Lió P. A hybrid of metabolic flux analysis and bayesian factor modeling for multiomic temporal pathway activation. ACS Synthetic Biol. doi: 10.1021/sb5003407.
46. Schilling CH, Edwards JS, Letscher D, Palsson BØ, et al. Combining pathway analysis with flux balance analysis for the comprehensive study of metabolic systems. Biotechnol Bioeng. 2000; 71(4):286-306.
47. Mazat JP, Reder C, Letellier T. Why are most flux control coefficients so small?J Theor Biol. 1996; 182(3):253-8. doi: 10.1006/jtbi.1996.0162.
48. Cascante M, Boros LG, Comin-Anduix B, de Atauri P, Centelles JJ, Lee PW-N. Metabolic control analysis in drug discovery and disease. Nat Biotechnol. 2002; 20(3):243-9. doi: 10.1038/nbt0302-243.
49. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Nucleic Acids Res:1-13. doi: 10.1093/nar/gkv007.
50. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeño-Tárraga AM, Wang H, Holden MTG, Wright A, Churcher C, Quail Ma, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabbinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet. 2006; 38(7):779-86. doi: 10.1038/ng1830.
51. Karasawa T, Ikoma S, Yamakawa K, Nakamura S. A defined growth medium for Clostridium difficile. Microbiology. 1995; 141(2):371-5. doi: 10.1099/13500872-141-2-371.
52. Janoir C, Denève C, Bouttier S, Barbut F, Hoys S, Caleechum L, Chapetón-Montes D, Pereira FC, Henriques AO, Collignon A, Monot M, Dupuy B. Adaptive strategies and pathogenesis of Clostridium difficile from In vivo transcriptomics. Infect Immun. 2013; 81(10):3757-69. doi: 10.1128/IAI.00515-13.
53. Kleessen S, Laitinen R, Fusari CM, Antonio C, Sulpice R, Fernie AR, Stitt M, Nikoloski Z. Metabolic efficiency underpins performance trade-offs in growth of Arabidopsis thaliana,. Nat Commun. 2014; 5:3537. doi: 10.1038/ncomms4537.
54. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30(1):207-10. doi: 10.1093/nar/30.1.207.
55. Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang YA, Williams E, Dylag M, Kurbatova N, Brandizi M, Burdett T, Megy K, Pilicheva E, Rustici G, Tikhonov A, Parkinson H, Petryszak R, Sarkans U, Brazma A. ArrayExpress update-simplifying data submissions. Nucleic Acids Res. 2015; 43(D1):1113-6. doi: 10.1093/nar/gku1057.
56. Gerber M, Walch C, Löffler B, Tischendorf K, Reischl U, Ackermann G. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J Med Microbiol. 2008; 57(6):776-83. doi: 10.1099/jmm.0.47739-0.
57. Cattoir V, Ould-Hocine ZF, Legrand P. Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital. Pathologie Biologie. 2008; 56(7-8):407-11. doi: 10.1016/j.patbio.2008.07.022.
58. Beran V, Chmelar D, Vobejdova J, Konigova A, Nemec J, Tvrdik J. Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains. Folia Microbiologica. 2014; 59(3):209-15. doi: 10.1007/s12223-013-0283-1.
59. Emerson JE, Stabler RA, Wren BW, Fairweather NF. Microarray analysis of the transcriptional responses of Clostridium difficile to environmental and antibiotic stress. J Med Microbiol. 2008; 57(6):757-64. doi: 10.1099/jmm.0.47657-0.
60. Jozefczuk S, Klie S, Catchpole G, Szymanski J, Cuadros-Inostroza A, Steinhauser D, Selbig J, Willmitzer L. Metabolomic and transcriptomic stress response of Escherichia coli. Mol Syst Biol. 2010; 6(1):364. doi: 10.1038/msb.2010.18.
61. Dubois T, Dancer-Thibonnier M, Monot M, Hamiot A, Bouillaut L, Soutourina O, Martin-Verstraete I, Dupuy B. Control of Clostridium difficile physiopathology in response to cysteine availability. Infect Immun. 2016; 84(8):2389-405. doi: 10.1128/IAI.00121-16.
62. Juhas M, Eberl L, Church GM. Essential genes as antimicrobial targets and cornerstones of synthetic biology. Trends Biotechnol. 2012; 30(11):601-7. doi: 10.1016/j.tibtech.2012.08.002.
63. Dembek M, Barquist L, Boinett CJ, Cain AK, Mayho M, Lawley TD, Fairweather NF, Fagan RP. High-throughput analysis of gene essentiality and sporulation in Clostridium difficile. mBio. 2015;6(2). doi: 10.1128/mBio.02383-14.
64. Tatusova T, Dicuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 2016; 44(14):6614-24. doi: 10.1093/nar/gkw569.